Innovinc International welcomes you to attend the Innovations in "5th World Congress on Cancer Research & Therapy" during September 09 - 11, 2019 London, UK. We cordially invite all the participants who are interested in sharing their knowledge and research in the arena of Cancer/Oncology.
WCCRT- 2019 anticipates more than 120 participants around the globe with thought-provoking Keynote lectures, Oral and Poster presentations. This is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Deans of Cancer organizations and centers, Academic, Research and Clinical Professors, Directors of universities and Oncologists. It is an excellent event for students to meet and discuss with lead researchers. The conference provides an unprecedented opportunity to discover innovation in the area of Cancer/oncology and new business opportunities. It is among the most important events in terms of international regulatory policies and it is open to the participation of private companies.
Participants from the top international academic, government and private industry labs of different disciplines participate in WCCRT-2019 to identify new technology trends, development tools, product opportunities, R&D collaboration`s, and commercialization partners. It is an excellent event for students to meet and discuss with lead researchers. The conference provides an unprecedented opportunity to discover innovation in the area of Cancer and Oncology. It is among the most important events in terms of international regulatory policies and it is open to the participation of private companies.
Cannabinoids are widely used in the management of pain, nausea and cachexia in cancer patients. However, there has been no objective clinical evidence of any anticancer activity yet. The aim of this study was to assess the effects of pharmaceutical-grade synthetic cannabidiol on a range of cancer patients.
Project Data Sphere (PDS) is a research platform that provides the research community with broad access to both de-identified patient-level data from oncology clinical trials and related analytic tools. While these data are rich in measures that characterize the clinical trials under study, data providers are required to de-identify patient-level data by removing key demographic data.
Abundant research conducted in the past decade has powered an explosion in our understanding of cancer genomics in the development and progression of cancer, and significantly enhanced our ability to translate this ever-increasing knowledge for the management of cancer patients.
Adult T-cell leukemia/lymphoma (ATLL) is an often-fatal malignancy that responds poorly to chemotherapy. The virally-encoded transcription factor HBZ, the only HTLV-1 encoded factor that is expressed on all ATLL cases, binds to an ATLL specific BATF3 super-enhancer and thereby regulates the expression of BATF3 and downstream targets including MYC.
The endometrial tissue is an extremely sensitive target for sex hormones capable to transform its functions and structure promptly in order to meet its pivotal role in human reproduction. Hormonal induced changes occur physiologically during menarche, menstrual cycles and menopause.
Cancer heterogeneity and dynamic adaptation require novel strategies for accurate detection, imaging, and precision treatment. Light-based technologies provide unique capabilities to address some critical issues in cancer research. One area of immense need is to improve the precision of cancer resection.
This lecture provides an overview of recent developments in our laboratory for several plasmonic nanoplatforms and biosensing technologies that allow biomedical diagnostics from the gene level to single-cell, and whole body systems. Plasmonics refers to the research area of enhanced electromagnetic properties of metallic nanostructures that produce ultrasensitive and selective detection technologies.
Copyrights © 2016-17 Innovinc Pvt Ltd All Rights Reserved